Ryu, Y.K.; Ricker, E.C.; Soderquist, C.R.; Francescone, M.A.; Lipsky, A.H.; Amengual, J.E.
Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 4928.
https://doi.org/10.3390/jcm11164928
AMA Style
Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE.
Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine. 2022; 11(16):4928.
https://doi.org/10.3390/jcm11164928
Chicago/Turabian Style
Ryu, Yun Kyoung, Edd C. Ricker, Craig R. Soderquist, Mark A. Francescone, Andrew H. Lipsky, and Jennifer E. Amengual.
2022. "Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma" Journal of Clinical Medicine 11, no. 16: 4928.
https://doi.org/10.3390/jcm11164928
APA Style
Ryu, Y. K., Ricker, E. C., Soderquist, C. R., Francescone, M. A., Lipsky, A. H., & Amengual, J. E.
(2022). Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine, 11(16), 4928.
https://doi.org/10.3390/jcm11164928